Nycomed’s proton-pump inhibitor pantoprazole is set to become the second non-prescription medicine authorised through Europe’s centralised procedure, following orlistat.
The European Medicines Agency (EMEA) said on 19 February that it had adopted positive opinions for five non-prescription medicines from Nycomed containing 20mg pantoprazole. The OTC medicines are indicated for short-term treatment in adults of reflux symptoms, such as heartburn and regurgitation.
Once the European Commission has adopted the opinions, the five products will be authorised as non-prescription medicines in all 27 member states of the European Union.
At present, pantoprazole is only available without a prescription in Australia, Mexico and Sweden. It is still protected by patents in major European markets.
No comments:
Post a Comment